Literature DB >> 15240115

Dominant negative 14-3-3 promotes cardiomyocyte apoptosis in early stage of type I diabetes mellitus through activation of JNK.

Narasimman Gurusamy1, Kenichi Watanabe, Meilei Ma, Shaosong Zhang, Anthony J Muslin, Makoto Kodama, Yoshifusa Aizawa.   

Abstract

14-3-3 family members are dimeric, phosphoserine binding proteins that regulate signal transduction, apoptotic, and checkpoint control pathways. Recently, cardiomyocyte apoptosis has been characterized in type I diabetes mellitus. In order to study the molecular mechanism underlying diabetes-induced cardiomyocyte apoptosis, we examined the role of 14-3-3 protein and MAPK pathways in transgenic mice with cardiac specific expression of dominant negative 14-3-3eta (DN-14-3-3). p38 MAPK was highly activated 1, 28, and 56 days after diabetes induction by streptozotocin, whereas peak JNK activation was found on day 3 and decreased afterwards. In contrast, ERK1/2 were not activated in diabetic myocardium. Cardiomyocyte apoptosis was peaked on day 3 and decreased on 7, 28, and 56 days. p38 MAPK and JNK activation as well as cardiomyocyte apoptosis were greatly increased in DN-14-3-3 mice relative to non-transgenic mice. Moreover, we found a significant correlation between JNK activation and apoptosis in diabetic myocardium. These results indicate for the first time that 14-3-3 protein plays a critical anti-apoptotic role in diabetic myocardium by inhibiting the JNK pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240115     DOI: 10.1016/j.bbrc.2004.06.023

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  High glucose-induced repression of RAR/RXR in cardiomyocytes is mediated through oxidative stress/JNK signaling.

Authors:  Amar B Singh; Rakeshwar S Guleria; Irina T Nizamutdinova; Kenneth M Baker; Jing Pan
Journal:  J Cell Physiol       Date:  2012-06       Impact factor: 6.384

2.  P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin.

Authors:  Merit E Reyes-Reyes; Margaret D George; John D Roberts; Steven K Akiyama
Journal:  Exp Cell Res       Date:  2006-09-16       Impact factor: 3.905

Review 3.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.

Authors:  Guanghong Jia; Michael A Hill; James R Sowers
Journal:  Circ Res       Date:  2018-02-16       Impact factor: 17.367

4.  Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy.

Authors:  Kenichi Watanabe; Rajarajan A Thandavarayan; Meilei Harima; Flori R Sari; Narasimman Gurusamy; Punniyakoti T Veeraveedu; Sayaka Mito; Wawaimuli Arozal; Vijayakumar Sukumaran; Arun Prasath Laksmanan; Vivian Soetikno; Makoto Kodama; Yoshifusa Aizawa
Journal:  Curr Cardiol Rev       Date:  2010-11

5.  Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo: Effects on Cardiac Fibrosis and Hypertrophy.

Authors:  Wawaimuli Arozal; Flori R Sari; Kenichi Watanabe; Somasundaram Arumugam; Punniyakoti T Veeraveedu; Meilei Ma; Rajarajan A Thandavarayan; Vijayakumar Sukumaran; Arun Prasath Lakshmanan; Yoshiyasu Kobayashi; Sayaka Mito; Vivian Soetikno; Kenji Suzuki
Journal:  ISRN Pharmacol       Date:  2011-04-14

Review 6.  14-3-3 protein regulation of excitation-contraction coupling.

Authors:  Walter C Thompson; Paul H Goldspink
Journal:  Pflugers Arch       Date:  2021-11-25       Impact factor: 3.657

7.  Stellaria media tea protects against diabetes-induced cardiac dysfunction in rats without affecting glucose tolerance.

Authors:  Virág Demján; Andrea Sója; Tivadar Kiss; Alexandra Fejes; Flóra Diána Gausz; Gergő Szűcs; Andrea Siska; Imre Földesi; Roland Tengölics; Zsuzsanna Darula; Dezső Csupor; Márton Pipicz; Tamás Csont
Journal:  J Tradit Complement Med       Date:  2021-08-10

8.  Gastrodin Protects Cardiomyocytes from Anoxia/Reoxygenation Injury by 14-3-3η.

Authors:  Meifang Zhu; Wei Deng; Suhong Di; Mingming Qin; Dan Liu; Bo Yi
Journal:  Oxid Med Cell Longev       Date:  2018-07-25       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.